Timothy Bassett, M.D., of Northport Medical Center in Tuscaloosa, Alabama, performed the first EVOS-HA surgery in the United States on October 21, 2015 for an L4-L5 revision of a failed titanium cage and a non-union in addition to a L5-S1 TLIF.
First EVOS-HA PEEK-OPTIMA Implant Installed
1 min read Premium comments
Secondary
The EVOS-HA, made by Cutting Edge Spine of Waxhaw, North Carolina, is the first FDA cleared PEEK-OPTIMA Lumbar Interbody system in the U.S. to be impregnated with hydroxyapatite (HA). HA is claimed by the manufacturer to encourage bone growth as well as providing the strength, versatility, and advantages of its predecessor, PEEK-OPTIMA Natural.
“The EVOS-HA represents a significant step forward in the world of lumbar interbody fusions, ” said Bassett. “The combination of the new PEEK-OPTMA HA enhanced biomaterials with the anatomically contoured implant design, leads me to believe that the technology may help us obtain higher fusion rates, better subsidence resistance, lordosis, and overall cleaner line to line fit. The improved modulus, in addition to the ability for bone on-growth to the implant, makes it an ideal material for biologic fusion.”
The EVOS-HA is Cutting Edge Spine’s flagship product, according to Randy Roof, CES President and Co-Founder. He expressed himself as being confident that the product will become the gold standard for patients suffering from degenerative lumbar disc disease who are in need of a fusion. Cutting Edge Spine is a privately owned medical device organization that was founded in 2010.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.